ArticleOrphanet journal of rare diseases2026
Identification of a novel ACADSB variant for the presymptomatic diagnosis of 2-Methylbutyryl-CoA dehydrogenase deficiency through newborn screening in Iran.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background2-Methylbutyryl-CoA dehydrogenase deficiency (2-MBDD), also known as short/branched-chain acyl-CoA dehydrogenase (SBCAD) deficiency, is a rare inborn error of metabolism classified as an organic acidemia. Early detection through neonatal screening is crucial to prevent irreversible complications. This study reports the first documented case of 2-MBDD in Iran, identified through the national neonatal screening program in 2022. MATERIALS AND
methodsMetabolic screening was performed on dried blood spots (DBS) using electrospray ionization tandem mass spectrometry (ESI-MS/MS). Urine organic acid analysis was conducted via gas chromatography-mass spectrometry (GC/MS). Comprehensive clinical assessments, including ophthalmologic and audiologic evaluations, electroencephalography (EEG), echocardiography, and brain magnetic resonance imaging (MRI), were performed. Whole-exome sequencing (WES) was used to confirm the diagnosis.
resultsA male neonate, delivered by cesarean section, was asymptomatic at birth. Initial metabolic screening revealed elevated 2-methylbutyrylcarnitine (C5) levels, confirmed by urine organic acid analysis and genetic testing, which identified a novel likely pathogenic variant in the ACADSB gene (c.907G > C; p.G303R). The infant was managed with a carnitine-supplemented diet and continued breastfeeding. Regular follow-ups demonstrated normal growth, neurodevelopmental milestones, and biochemical parameters, with no abnormalities detected. Post-treatment, C5 levels stabilized at 0.4 µmol/L, within the intermediate range.
conclusionThis case underscores the pivotal role of neonatal screening in the early diagnosis and management of rare metabolic disorders. Timely intervention can prevent severe complications and improve clinical outcomes, highlighting the need for expanded newborn screening programs and population-specific genetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.